Credence

Evotec, Bristol Myers Squibb Secure Second IND Clearance Under Protein Degradation Collaboration


Key Points

  • The FDA has accepted an IND for a second molecular glue CELMoD candidate from the Evotec and Bristol Myers Squibb protein degradation collaboration, with Phase 1 expected in 2027.
  • The first candidate from the collaboration entered Phase 1 in March 2026 for advanced clear cell renal cell carcinoma.
  • The partnership, begun in 2018, combines Evotec's multi-omics and AI platforms with Bristol Myers Squibb's CELMoD library to develop molecular glue degraders, mainly in oncology.

Evotec and Bristol Myers Squibb have reached another clinical development milestone in their ongoing protein degradation partnership, with the U.S. Food and Drug Administration (FDA) accepting an Investigational New Drug (IND) application for a second molecular glue candidate.

The newly cleared candidate, a cereblon E3 ligase modulator (CELMoD), is expected to advance into a Phase 1 clinical trial in 2027. It follows the first drug candidate developed through the collaboration, which entered Phase 1 testing in March 2026 for patients with advanced clear cell renal cell carcinoma.

The latest milestone adds to the partners’ pipeline of molecular glue degraders and highlights continued progress in applying targeted protein degradation to diseases with significant unmet medical needs.

The collaboration, first established in 2018 and expanded in 2022, brings together Evotec’s multi-omics screening, AI-enabled data analytics and drug design capabilities with Bristol Myers Squibb’s proprietary library of CELMoD agents. The companies are using these complementary technologies and resources to identify and advance molecular glue compounds against challenging therapeutic targets, primarily in oncology.

“Advancing a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform,” says Dr. Joanna Holbrook, Chief Scientific Officer of Evotec. She noted that the achievement reflects the partners’ ability to translate complex biological insights into development candidates and supports the potential to build a broader pipeline of investigational therapies.

Unlike conventional small-molecule drugs, which generally work by inhibiting or activating a protein’s function, molecular glue degraders are designed to eliminate specific proteins from cells. These compounds promote interactions between an E3 ubiquitin ligase and a target protein, triggering a process known as ubiquitination that marks the target for degradation. This approach offers an alternative way to address proteins that have historically been difficult to target using traditional drug discovery methods.

CELMoDs work by inducing new interactions between cereblon (CRBN), an E3 ubiquitin ligase, and selected substrate proteins. By redirecting the cell’s natural protein degradation machinery, these compounds may enable researchers to address a broader range of biological targets than conventional inhibitors or agonists.

Evotec began its strategic molecular glue drug discovery and development collaboration with Celgene in 2018, before the company became part of Bristol Myers Squibb. The partnership draws on Bristol Myers Squibb’s experience and proprietary CELMoD compound library, alongside Evotec’s PanOmics and PanHunter platforms and its AI- and machine learning-supported drug discovery capabilities.

Evotec uses large-scale proteomics and transcriptomics to evaluate cellular responses and identify promising drug candidates. Its PanOmics platform generates extensive biological data, while PanHunter supports the integration and analysis of those datasets to help prioritize candidates for further development and lead optimization.

Learn more at www.evotec.com.